CRISPR / Cas14a coupled TdT electrochemical biosensor and preparation method and application thereof
Through CRISPR/Cas14a-coupled TdT electrochemical biosensor, the low specificity and expensive equipment of exosome detection in early diagnosis of nasopharyngeal carcinoma are solved, and high sensitivity and high specificity of exosome detection from nasopharyngeal carcinoma is achieved , laying the theoretical foundation for the early diagnosis of nasopharyngeal carcinoma.
Patent Information
- Application Number
- CN202411263509.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-10
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
In the early diagnosis of nasopharyngeal carcinoma, the exosome detection has problems such as low specificity, expensive equipment and complex operation, and it is difficult to achieve high sensitivity and high specificity of nasopharyngeal carcinoma-derived exosome detection.
Electrochemical biosensors using CRISPR/Cas14a-coupled TdT, magnetic nanoparticles modified by streptavidin, biotin-modified aptamers, base-complementary probes, terminal deoxynucleotide transferases and deoxythoracic thorax Components such as glycoside triphosphate are constructed to construct the CRISPR-Cas14 system and combine it with gold electrodes to achieve high specificity and high sensitivity detection of exosomes from nasopharyngeal carcinoma.
It realizes high specificity and high sensitivity detection of exosomes from nasopharyngeal carcinoma, simplifies operation, reduces equipment requirements, improves the sensitivity and specificity of the detection, and provides a theoretical basis for the early diagnosis of nasopharyngeal carcinoma.
Smart Images

Figure CN118914330A_ABST
Abstract
Citation Information
Cited By
Electrochemical biosensor based on TdT-Cas12a reaction system and HaeIII enzyme and Alzheimer's biomarker detection method
CN121453876A
